Literature DB >> 21908879

Improving the FDA's advisory committee process.

Eric P Brass1, William R Hiatt.   

Abstract

Mesh：

Year:  2011        PMID： 21908879     DOI： 10.1177/0091270011412962

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN： 0091-2700            Impact factor:   3.126


× No keyword cloud information.
  4 in total

1.  The Food and Drug Administration and the Future of Drug Development for the Treatment of Diabetes.

Authors:  Eric P Brass
Journal:  Diabetes Spectr       Date:  2014-05

2.  Widening consumer access to medicines: a comparison of prescription to non-prescription medicine switch in Australia and New Zealand.

Authors:  Natalie J Gauld; Fiona S Kelly; Lynne M Emmerton; Stephen A Buetow
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

3.  Why are self-medication opportunities limited in Austria? An interview study and comparison with other countries.

Authors:  Natalie J Gauld; Christoph A Baumgärtel; Stephen A Buetow
Journal:  PLoS One       Date:  2021-01-25       Impact factor: 3.240

4.  Assessing the benefit-risk for new drugs: are the FDA's Endocrinologic and Metabolic Drugs Advisory Committee and the Division of Metabolism and Endocrinology Products in sync?

Authors:  Eric P Brass
Journal:  Diabetes Care       Date:  2013-05-21       Impact factor: 19.112
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.